HILPDA as a Radioligand Therapy Target
HILPDA, hypoxia inducible lipid droplet associated, is a cell-surface protein. In Human Protein Atlas immunohistochemistry, HILPDA staining is highest in testicular cancer (100% of samples positive), colorectal cancer (100% of samples positive) and bladder cancer (100% of samples positive). Clinical status: Discovery-stage (no clinical drug program).
Is HILPDA a good radioligand therapy target?
Scored against the six criteria that decide whether a protein can become a radioligand therapy:
- ✅ Cell-surface accessibility: Localized to the cell surface, so a radioligand can reach it from circulation.
- ✅ Tumor expression: High IHC staining in testicular cancer, 100% of samples positive.
- ❔ Internalization: Not yet assessed.
- ⚠️ Clinical precedent: Discovery-stage (no clinical drug program)
- ❔ Shedding: Not yet assessed.
- ❔ Normal-tissue dosimetry: Check kidney, liver, bone marrow and salivary expression in the Human Protein Atlas tissue atlas.
HILPDA expression in cancer
Protein expression of HILPDA across 20 cancer types from Human Protein Atlas immunohistochemistry. The score is a weighted staining intensity from 0 to 1; "% positive" is the share of patient samples with detectable staining.
| Cancer type | IHC score | Level | % positive |
|---|---|---|---|
| Testicular Cancer | 0.73 | High | 100% |
| Colorectal Cancer | 0.69 | High | 100% |
| Bladder Cancer | 0.61 | High | 100% |
| Endometrial Cancer | 0.60 | High | 100% |
| Neuroendocrine Tumors | 0.58 | High | 75% |
| Head and Neck Cancer | 0.56 | High | 100% |
| Prostate Cancer | 0.56 | High | 92% |
| Ovarian Cancer | 0.55 | High | 100% |
| Breast Cancer | 0.47 | Medium | 92% |
| Cervical Cancer | 0.47 | Medium | 83% |
| Kidney Cancer | 0.47 | Medium | 75% |
| Gastric Cancer | 0.42 | Medium | 82% |
| Melanoma | 0.42 | Medium | 75% |
| Pancreatic Cancer | 0.42 | Medium | 75% |
| Lymphoma | 0.36 | Medium | 75% |
| Lung Cancer | 0.36 | Medium | 75% |
| Thyroid Cancer | 0.33 | Medium | 100% |
| Skin Cancer | 0.28 | Medium | 58% |
| Liver Cancer | 0.19 | Low | 50% |
| Glioma | 0.14 | Low | 42% |
Is HILPDA internalized?
Nuclens has not yet extracted internalization evidence for HILPDA. Internalization matters for radioligands because an internalizing receptor traps the radionuclide inside the tumor cell. Run a full analysis to pull the latest literature.
HILPDA clinical trials
Discovery-stage (no clinical drug program). Nuclens hasn't indexed trials for HILPDA yet. Search ClinicalTrials.gov for HILPDA trials.
HILPDA normal tissue expression
Normal-tissue expression in dose-limiting organs (kidney, liver, bone marrow, salivary glands) drives radioligand dosimetry risk. Nuclens is re-validating its normal-tissue values, so they are not shown here yet. See HILPDA in the Human Protein Atlas tissue atlas, and read how normal-tissue expression predicts radioligand dosimetry risk.
HILPDA gene essentiality (DepMap)
CRISPR knockout effect across 1258 cancer cell lines: 0.13 (not essential). Radioligands kill by radiation, not by blocking the target, so essentiality matters less than for inhibitors. A non-essential target can still be an excellent radioligand target.
Related testicular cancer radioligand targets
HER3 (ERBB3) · c-MET (MET) · STEAP2 · KIT · SSTR2 · TMEFF2 · Mesothelin (MSLN) · HER2 (ERBB2)
See all radioligand therapy targets in testicular cancer.
See how HILPDA ranks against 15,000 targets for your indication.
Run a free analysisData sources
Subcellular localization: UniProt via Open Targets (CC BY 4.0 / CC0). Tumor immunohistochemistry: Human Protein Atlas (CC BY-SA 4.0). Clinical trials: ClinicalTrials.gov (public domain). Gene essentiality: DepMap (CC BY 4.0). Internalization and shedding: AI-extracted from PubMed abstracts, so verify against the cited papers before relying on them. Nuclens is a first-pass triage layer, not a substitute for wet-lab validation or clinical dosimetry. Derived expression data on this page is shared under CC BY-SA 4.0.